June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Long-term effects of anti-VEGF injections on intraocular pressure in patients with age-related macular degeneration and diabetic macular edema
Author Affiliations & Notes
  • Blake Williams
    Pritzker School of Medicine, University of Chicago, Chicago, IL
  • Ashiyana Nariani
    University of Chicago, Chicago, IL
  • Shirish Poudyal
    Pritzker School of Medicine, University of Chicago, Chicago, IL
  • Seenu M Hariprasad
    Ophthalmology, University of Chicago, Chicago, IL
  • Footnotes
    Commercial Relationships Blake Williams, None; Ashiyana Nariani, None; Shirish Poudyal, None; Seenu Hariprasad, Alcon (C), Alcon (R), Allergan (C), Allergan (R), Bayer (C), Bayer (R), Clearside Biomedical (C), Genentech (C), Genentech (R), Ocular Therapeutix (C), OD-OS (C), Optos (F), Regeneron (C), Regeneron (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1800. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Blake Williams, Ashiyana Nariani, Shirish Poudyal, Seenu M Hariprasad; Long-term effects of anti-VEGF injections on intraocular pressure in patients with age-related macular degeneration and diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1800.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

There is debate in the ophthalmology community about whether anti-VEGF injections result in a long-term increase in intraocular pressure (IOP). Some studies have identified risk factors (i.e. number of injections, interval between injections) that are associated with elevated IOP, while other studies have shown that intravitreal anti-VEGF injections do not lead to elevated IOP. We performed a retrospective, observational clinical study to investigate how the number and timing of intravitreal injections for patients with age-related macular degeneration (AMD) and diabetic macular edema (DME) affect IOP over time.

 
Methods
 

After receiving IRB approval, we collected long-term IOP data on patients receiving anti-VEGF injections at the University of Chicago. Patients over the age of 40 who received the injections for AMD (n = 76) or DME (n = 55) were included in the study; those receiving injections for retinal vein occlusion were excluded. Patients were grouped according to indication for injection as well as number of injections received (1-3, 4-6, 7-9, or 10+ injections). IOP measurements were then placed into time points (0-6, 6-12, 12-18, 18-24, or 24+ months after first injection) and compared to the pre-injection IOP. One-tailed t-tests were used for statistical analysis.

 
Results
 

For patients with DME, average initial IOP was 15.7 mmHg. At 24+ months after injection, the average IOP was 15.2 (95% CI: 13.8-16.6, p = 0.68) for patients receiving 1-3 injections, 16.8 (15.3-18.3, p = 0.23) for 4-6 injections, and 14.4 (13.8 - 15.0, p = 0.66) for 7-9 injections. For patients with AMD, average initial IOP was 15.6 mmHg. At 24+ months after injection, the average IOP was 12.6 (95% CI: 10.8-14.4, p = 0.97) for patients receiving 1-3 injections, 14.9 (13.7-16.1, p = 0.96) for 4-6 injections, 14.8 (12.4-17.2, p = 0.84) for 7-9 injections, and 15.7 (14.0-17.4, p=0.56) for 10+ injections.

 
Conclusions
 

There was no statistically significant increase in IOP over time for AMD or DME patients, regardless of the number injections received. Ours is the only study we are aware of to track the progression of IOP over a period of greater than two years and to stratify by number of injections received. It is notable that neither of these variables affected IOP, as they have been proposed as potential factors contributing to increased IOP after injections  

 

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×